WALTHAM, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it ...
NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (Nasdaq:CKPT), a Fortress Biotech (Nasdaq:FBIO) company, today announced the pricing of its ...
Checkpoint Therapeutics (NASDAQ:CKPT) just reported results for the first quarter of 2024. Checkpoint Therapeutics reported earnings per share of -33 cents. This was below the analyst estimate for EPS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results